Patents by Inventor David W. Andrews

David W. Andrews has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12104746
    Abstract: An example deployable structure includes at least one base member, at least one first articulable member, at least one second articulable member, and at least one interference member. The deployable structure must include at least one base member, at least one first articulable member, at least one second articulable member, and at least one interference member otherwise the deployable structure may not be switchable between the compact and deployed states thereof. The base member is articulably connected to the first articulable member using a first hinge, the first articulable member is articulably connected to the second articulable member using a second hinge, and the interference member is articulably connected to the second articulable member using a third hinge. The interference member is also attached to the base member, for example, using a fourth hinge. The deployable structure is configured to switch from at least a compact state to a deployed state.
    Type: Grant
    Filed: April 21, 2022
    Date of Patent: October 1, 2024
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: David W. Andrews, Spencer P. Magleby, Larry L. Howell
  • Patent number: 12064446
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: August 20, 2024
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20240100078
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Application
    Filed: September 21, 2023
    Publication date: March 28, 2024
    Inventors: David W. Andrews, Douglas C. Hooper
  • Patent number: 11801259
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: October 31, 2023
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20220341540
    Abstract: An example deployable structure includes at least one base member, at least one first articulable member, at least one second articulable member, and at least one interference member. The deployable structure must include at least one base member, at least one first articulable member, at least one second articulable member, and at least one interference member otherwise the deployable structure may not be switchable between the compact and deployed states thereof. The base member is articulably connected to the first articulable member using a first hinge, the first articulable member is articulably connected to the second articulable member using a second hinge, and the interference member is articulably connected to the second articulable member using a third hinge. The interference member is also attached to the base member, for example, using a fourth hinge. The deployable structure is configured to switch from at least a compact state to a deployed state.
    Type: Application
    Filed: April 21, 2022
    Publication date: October 27, 2022
    Inventors: David W. Andrews, Spencer P. Magleby, Larry L. Howell
  • Publication number: 20220195440
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In some embodiments, the AS are provides in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomem of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma. In some embodiments, the method are provided to predict the effectiveness of antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R) in a subject.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 23, 2022
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20220133775
    Abstract: Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 5, 2022
    Applicants: Bio-Path Holdings, Inc., Thomas Jefferson University
    Inventors: Ana Ashizawa, Douglas Craig Hooper, David W. Andrews
  • Publication number: 20220072025
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Application
    Filed: July 1, 2021
    Publication date: March 10, 2022
    Inventors: David W. Andrews, Douglas C. Hooper
  • Patent number: 11077133
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: August 3, 2021
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20210060055
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Application
    Filed: September 15, 2020
    Publication date: March 4, 2021
    Inventors: David W. Andrews, Douglas C. Hooper
  • Patent number: 10772904
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: September 15, 2020
    Assignee: THOMAS JEFFERSON UNIVERSITY
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20200197435
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Application
    Filed: December 12, 2019
    Publication date: June 25, 2020
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20200054761
    Abstract: The present disclosure provides methods and compositions for enhancing the treatment of a cancer, particularly in a human subject, by administering antibody drug conjugates (ADCs) to inhibit or kill specific myeloid/monocyte/macrophage-lineage cells. The myeloid/monocyte/macrophage-lineage cells are identified, for example, by expression of one or more of the scavenger receptors CD204 and CD163, and/or mannose receptor-1 (CD206).
    Type: Application
    Filed: February 22, 2018
    Publication date: February 20, 2020
    Applicants: Thomas Jefferson University, Imvax, Inc.
    Inventors: David W. Andrews, Douglas C. Hooper, Arthur Howe
  • Publication number: 20200038429
    Abstract: Provided herein are methods of treating cancer or an autoimmune disease comprising administering a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide that targets a IGF-1R-encoding polynucleotide.
    Type: Application
    Filed: April 19, 2018
    Publication date: February 6, 2020
    Applicants: Bio-Path Holdings, Inc., Thomas Jefferson University
    Inventors: Ana Ashizawa, Douglas Craig Hooper, David W. Andrews
  • Patent number: 10543226
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 28, 2020
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20190365794
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Application
    Filed: July 22, 2019
    Publication date: December 5, 2019
    Applicant: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Patent number: 10357509
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: July 23, 2019
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Patent number: 10265339
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 23, 2019
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Patent number: 10206942
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Grant
    Filed: April 11, 2016
    Date of Patent: February 19, 2019
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper
  • Publication number: 20180271894
    Abstract: The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 27, 2018
    Applicant: THOMAS JEFFERSON UNIVERSITY
    Inventors: David W. Andrews, Douglas C. Hooper